{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:17Z","timestamp":1761870317826,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clml.2011.10.002","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T04:59:07Z","timestamp":1321592347000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea"],"prefix":"10.1016","volume":"12","author":[{"given":"Ho Sup","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Chun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kil Min","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeon Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong Jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo Kon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.10.002_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1054\/blre.2001.0158","article-title":"Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management","volume":"15","author":"Tefferi","year":"2001","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2011.10.002_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2003.50030","article-title":"Indications for lowering platelet numbers in essential thrombocythemia","volume":"40","author":"Barbui","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2011.10.002_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.002_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/asheducation-2009.1.621","article-title":"Pathogenesis and management of essential thrombocythemia","volume":"2009","author":"Beer","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2011.10.002_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.002_bib6","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2005.01.001","article-title":"Risk-adapted therapy in essential thrombocythemia and polycythemia vera","volume":"19","author":"Finazzi","year":"2005","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2011.10.002_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.002_bib9","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib11","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib13","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.002_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.002_bib15","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat patients with polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-008-0531-7","article-title":"Long-term management of thrombocytosis in essential thrombocythaemia","volume":"88","author":"Birgegard","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.10.002_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.002_bib18","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2011.10.002_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1532\/IJH97.06009","article-title":"Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group","volume":"83","author":"Dan","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.10.002_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5045\/kjh.2008.43.2.83","article-title":"The efficacy and adverse effect of hydroxyurea as compared with anagrelide in essential thrombocythemia","volume":"43","author":"Seol","year":"2008","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.clml.2011.10.002_bib21","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.002_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2011.10.002_bib23","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.002_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hon.816","article-title":"Analysis of risk factors predicting thrombotic and\/or haemorrhagic complications in 306 patients with essential thrombocythemia","volume":"25","author":"Radaelli","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2011.10.002_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.002_bib26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.10.002_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH08-06-0396","article-title":"Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation","volume":"101","author":"Bang","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.10.002_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.002_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.002_bib30","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.002_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.002_bib32","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.002_bib33","first-page":"378","article-title":"Distinct hemostatic profile of leukocytes in essential thrombocythemia (ET) carrying the JAK2 V617F mutation","volume":"106","author":"Falanga","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2011.10.002_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.leukres.2006.09.005","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","volume":"31","author":"Speletas","year":"2007","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:46Z","timestamp":1761870106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011005520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S2152265011005520"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}